NKARTA, Inc.
Clinical trials sponsored by NKARTA, Inc., explained in plain language.
NKARTA, Inc.
NKTX
NASDAQ
Clinical-stage biotech developing natural killer cell therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Donor immune cells take on autoimmune kidney disease in early trial Results expected Apr 2027 (estimated)